Nicolas Villain MD, PhDAssociate Professor of Neurology, Sorbonne University - Assistance Publique Hôpitaux de Paris - Pitié-Salpêtrière Hospital, Paris, France
Dr. Nicolas Villain is an Associate Professor of Neurology (tenured position) at Sorbonne University, working at the Institute of Memory and Alzheimer's Disease, Department of Neurology, Pitié-Salpêtrière Hospital, Paris, France. He did his medical training with Prof. Bruno in Paris, and his PhD with Dr. Gaël Chételat in Caen, France, where he worked on multimodal neuroimaging and disconnection mechanisms in Alzheimer's disease. Besides clinical duties, he currently leads projects on brain network vulnerability using multimodal neuroimaging and on fluid biomarkers.
DisclosuresDr. Villain reports the following:
Independent of this work, NV received research support from Fondation Bettencourt-Schueller, Fondation Servier, Union Nationale pour les Intérêts de la Médecine (UNIM), Fondation Claude Pompidou, Fondation Alzheimer and Fondation pour la Recherche sur l’Alzheimer; travel grant from the Movement Disorders Society, Merz-Pharma, UCB Pharma, and GE Healthcare SAS; is an unpaid local principal investigator or sub-investigator in NCT04241068 and NCT05310071 (aducanumab, Biogen), NCT04437511 (donanemab, Eli-Lilly), NCT05463731 (remternetug, Eli-Lilly), NCT04592341 (gantenerumab, Roche), NCT03887455 (lecanemab, Eisai), NCT03352557 (gosuranemab, Biogen), NCT03828747 and NCT03289143 (semorinemab, Roche), NCT04619420 (JNJ-63733657, Janssen – Johnson & Johnson), NCT04374136 (AL001, Alector), NCT04592874 (AL002, Alector), NCT04867616 (bepranemab, UCB Pharma), NCT04777396 and NCT04777409 (semaglutide, Novo Nordisk), is an unpaid national coordinator for NCT05564169 (masitinib, ABScience); and has given unpaid lectures in symposia organized by Eisai and the Servier Foundation.